Regencell Bioscience Holdings (RGC) Total Debt (2020 - 2021)
Regencell Bioscience Holdings (RGC) reported Total Debt of $431969.0 for Q2 2021, down 85.93% on a YoY basis from $3.1 million in Q2 2020, and down 85.93% quarter-over-quarter from $3.1 million in Q2 2020.
Regencell Bioscience Holdings (RGC) Total Debt (2020 - 2021) Analysis & Trends
Regencell Bioscience Holdings has reported Total Debt for 2 years, with the latest figure at $431969.0 in Q2 2021.
- For the quarter ending Q2 2021, Total Debt fell 85.93% year-over-year to $431969.0; the trailing twelve-month figure through Jun 2021 stood at $431969.0 (down 85.93% YoY), and the FY2021 full-year result was $431969.0, down 85.93% from the prior year.
- Total Debt for Q2 2021 stood at $431969.0, down from $3.1 million in the prior quarter.
- The five-year high for Total Debt was $3.1 million in Q2 2020, with the low at $431969.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.63 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 9.05 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 3.53 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 3.99 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.51 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 570.41 Mn |
| 10 | Regencell Bioscience Holdings | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 431,969.00 |
| Jun 30, 2020 | 3.07 Mn |